đĸ đđ¨đĻđ§ đđĄ: Anthropic Partners With Six Life Sciences Firms to Accelerate AI-Powered Drug Development - $ANT $BMY
đ đđ˛đ đđļđ´đĩđšđļđ´đĩđđ:
⤠đđģđđĩđŋđŧđŊđļđ° partners with đ˛ đšđļđŗđ˛ đđ°đļđ˛đģđ°đ˛đ organizations to test Claude.
⤠Partners include đđŋđļđđđŧđš đ đđ˛đŋđ đĻđžđđļđ¯đ¯, đđļđ´đđŽđ, đđģđđ˛đąđŽ, đđļđđ˛đŋđ´đ˛đģđ°đ˛, đđ˛đģđ˛đŋđŽđđ˛, and đ§đĩđ˛ đđŧđšđđēđģ đđŋđŧđđŊ.
⤠đđ˛đģđ˛đŋđŽđđ˛ đđļđŧđēđ˛đąđļđ°đļđģđ˛đ designed a đŗđŦ% đđĩđŧđŋđđ˛đŋ CAR T-cell component using Claude.
⤠Modified design produced approximately đđŦđ đēđŧđŋđ˛ cancer-targeting receptors in lab tests.
⤠đđļđđ˛đŋđ´đ˛đģđ°đ˛ đđŽđ¯đ generated approximately đ¯đą,đŦđŦđŦ đŽđģđđļđ¯đŧđąđ đąđ˛đđļđ´đģđ in one month.
⤠đđģđđ˛đąđŽ used Claude to review đ,đŦđ˛đ đŊđŽđ´đ˛đ of manufacturing documentation.
⤠Claude identified đđ đ¸đģđŧđđģ đļđđđđ˛đ plus đŗ đŽđąđąđļđđļđŧđģđŽđš đļđđđđ˛đ, reducing review time đ´đĩ%.
⤠Claude drafted a regulatory document in đ° đĩđŧđđŋđ versus approximately đ¯ đēđŧđģđđĩđ.
⤠đđŋđļđđđŧđš đ đđ˛đŋđ đĻđžđđļđ¯đ¯ uses Claude for clinical trial planning and success estimates.
⤠Anthropic acquired đ đļđđĩđŋđļđš đ đ˛đąđļđ°đļđģđ˛ and launched đđšđŽđđąđ˛ đĻđ°đļđ˛đģđ°đ˛.
đ đĒđĩđ đ§đĩđļđ đ đŽđđđ˛đŋđ:
⤠Demonstrates AI's potential to đŽđ°đ°đ˛đšđ˛đŋđŽđđ˛ đąđŋđđ´ đąđļđđ°đŧđđ˛đŋđ and reduce development costs.
⤠Significant efficiency gains could transform đŊđĩđŽđŋđēđŽđ°đ˛đđđļđ°đŽđš đŋđ˛đđ˛đŽđŋđ°đĩ and regulatory workflows.
⤠Partnerships position đđģđđĩđŋđŧđŊđļđ° to expand into the high-value đ¯đļđŧđđ˛đ°đĩ đđ market.
⤠đđŋđļđđđŧđš đ đđ˛đŋđ đĻđžđđļđ¯đ¯ (đđ đŦ) gains AI-assisted clinical development capabilities.
⤠Early laboratory results remain preliminary and require đŗđđŋđđĩđ˛đŋ đđŽđšđļđąđŽđđļđŧđģ before clinical use.
đ đđ đŊđ˛đŋđ đĻđđŽđđ˛đēđ˛đģđ:
đ đļđ°đĩđŽđ˛đš đŖđŧđđŋđąđ˛đĩđģđŽđą, Senior Vice President and Head of Early Clinical Development at Bristol Myers Squibb:
"generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete."